5 (794) In stock
Crowther and Dolton et al. identified an unconventional human T cell clone capable of killing many different types of cancer in vitro in an HLA-independent fashion while sparing healthy cells. Using genome-wide CRISPR-Cas9 screening, the researchers showed that the T cell clone recognized the ubiquitously expressed, mostly monomorphic, MHC-I-related protein MR1 on the surface of cancer cells when MR1 was loaded with a yet unidentified cancer-specific or cancer-associated ligand. Adoptive transfer of this T cell clone into immunodeficient NSG mice with leukemia reduced tumor burden and increased survival.
IJMS, Free Full-Text
Michael G King Jr (@MichaelGKingJr) / X
IJMS, Free Full-Text
Immune-checkpoint inhibition for resectable non-small-cell lung
Grail's $1 Billion Bet on the Perfect Cancer Test
Genetic and pharmaceutical targeting of HIF1α allows combo
IJMS, Free Full-Text
Novel strategies for cancer immunotherapy: counter-immunoediting
Cancers, Free Full-Text
Discovery of a Pan-Cancer Killing T Cell
Novel strategies for cancer immunotherapy: counter-immunoediting
